How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification

Horst Neubauer; Sebastian Lask; Andreas Engelhardt; Andreas Mügge

doi:10.1160/TH07-10-0624

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2008; 99(02): 357-362
DOI: 10.1160/TH07-10-0624

Platelets and Blood Cells

Schattauer GmbH

How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification

Horst Neubauer

¹Clinic of Cardiology & Angiology, Ruhr University Bochum, Bochum, Germany

,

Sebastian Lask

¹Clinic of Cardiology & Angiology, Ruhr University Bochum, Bochum, Germany

,

Andreas Engelhardt

¹Clinic of Cardiology & Angiology, Ruhr University Bochum, Bochum, Germany

,

Andreas Mügge

¹Clinic of Cardiology & Angiology, Ruhr University Bochum, Bochum, Germany

› Institutsangaben

Abstract

Summary

The inhibitory platelet effect of clopidogrel is insufficient in approximately 5 to 30% of patients. These low responders (LR) face a significantly higher risk of cardiovascular complications. The therapeutic management of LR is still undefined. In the present study, we evaluate a novel therapeutic algorithm to reduce the incidence of clopidogrel resistance. One hundred sixty-one patients on 100 mg ofAspirin co-medication underwent elective coronary stenting and were given an initial dosage of 600 mg clopidogrel, followed by 75 mg clopidogrel daily. 48 h later, the platelet responsiveness was tested with ADP (5–20 μM) stimulation by impedance aggregometry (Chronolog 590). A significant rise in impedance (> 5 Ω after 6 minutes, aggregation index > 65%) was defined as LR. In this subgroup, platelets were stimulated with the selective P2Y₁₂-ADP receptor antagonist 2-MeS AMP. One hundred twenty-three patients were clopidogrel-responders (76.4%) and 38 patients were LR (23.6%). A defect of the ADP-receptor P2Y₁₂ was found in three out of 38 LR (7.9%). Inhibition of platelet aggregation indicating clopidogrel-responsiveness was achieved with either a clopidogrel high-dose regimen (22/38, 57.9%); a repeat loading dose, doubling the maintenance dose) or with an alternative therapy with ticlopidine (8/38 (21.1%); 250 mg twice daily).Thus the incidence of LR was reduced from 23.6% to 5.0%. Our aggregometer–guided therapeutic algorithm reduced the relative percentage of clopidogrel LR by 78.9%.This approach could prove to be helpful in achieving a further decrease in the incidence of clopidogrel resistance.

Keywords

Aggregation - clopidogrel - low-responder - resistance - ticlopidine

Volltext

Referenzen

References
1 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
3 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
4 Siller-Matula J, Schrör K, Wojta J. et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
5 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel. Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
6 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
7 Buonamici P, Marcucci R, Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
8 Morel O, Faure A, Ohlmann P. et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb Haemost 2007; 98: 896-869.
9 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
10 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
11 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
12 Cuisset T, Frere C, Quilici J. et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287.
13 Frere C, Cuisset T, Quilici J. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
14 Lau WC, Gurbel PA, Watkins PB. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-171.
15 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
16 Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-2207.
17 Williams DO. Clopidogrel pretreatment for percutaneous coronary intervention: double, double, dose in trouble?. Circulation 2005; 111: 2019-2021.
18 Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP. et al. Clopidogrel anti-platelet effect: An evaluation by optical aggregometry, impedance aggregometry, and the Platelet Function Analyzer (PFA-100®). Platelets 2007; 23: 1-6.
19 Ivandic BT, Schlick P, Staritz P. et al. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 2006; 52: 383-388.
20 Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 2005; 11: 25-35.
21 Andre P, La Rocca T, Delaney SM. et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108: 2697-2703.
22 Ko JW, Desta Z, Soukhova NV. et al. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 2000; 49: 343-351.
23 Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 2007; 98: 707-709.
24 Neubauer H, Mugge A. Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Des 2006; 12: 1271-1280.
25 Haque SF, Matsubayashi H, Izumi S. et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 2001; 48: 33-41.
26 Yee DL, Sun CW, Bergeron AL. et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 2723-2729.
27 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004; 16: 169-174.
28 Feher G, Koltai K, Alkonyi B. et al. Clopidogrel resistance: Role of body mass and concomitant medications. Int J Cardiol 2007; 120: 188-192.
29 Ferreira IA, Mocking AI, Feijge MA. et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-422.
30 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
31 Angiolillo DJ, Shoemaker SB, Desai B. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716.
32 Angiolillo DJ, Bernardo E, Ramirez C. et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006; 48: 298-304.
33 Neubauer H, Gunesdogan B, Hanefeld C. et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. Eur Heart J 2003; 24: 1744-1749.
34 Patti G, Colonna G, Pasceri V. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA- 2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-2106.
35 Angiolillo DJ, Fernández-Ortiz A, Bernardo E. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-1910.
36 Gurbel PA, Bliden KP, Hayes KM. et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396.
37 Kastrati A, von Beckerath N, Joost A. et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110: 1916-1919.
38 Angiolillo DJ. Tackling the diabetic platelet: is high clopidogrel dosing the answer?. J Thromb Haemost 2006; 4: 2563-2565.
39 Aleil B, Rochoux G, Monassier JP. et al. Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. J Thromb Haemost 2007; 5: 879-881.
40 Campo G, Valgimigli M, Gemmati D. et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. JAm Coll Cardiol 2007; 50: 1132-1137.